Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04331704
Other study ID # IRB201902818-N
Secondary ID UH3AA026214OCR31
Status Recruiting
Phase Phase 4
First received
Last updated
Start date January 12, 2021
Est. completion date August 31, 2024

Study information

Verified date November 2023
Source University of Florida
Contact Robert L. Cook, PhD
Phone (352) 273-5869
Email cookrl@ufl.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

80 young adult men will complete an initial survey and receive 1 of 2 types of alcohol and sexual health education and information to encourage prevention of alcohol-related problems, HIV and other sexually transmitted infections (STIs). Participants will then take pre-exposure prophylaxis (PrEP) for HIV prevention and complete a daily 5-minute, telephone-based interactive voice response (IVR) assessment of alcohol/substance use, sexual behavior and PrEP taking for 30 days. Medication will all be active PrEP. There is no placebo control in this study. Follow-up will occur after 30-days and 6-months later.


Recruitment information / eligibility

Status Recruiting
Enrollment 88
Est. completion date August 31, 2024
Est. primary completion date August 31, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 30 Years
Eligibility Inclusion Criteria: - Ability to read and write English - Consumption of 5 or more drinks per drinks in a day at least once in the past 30-days - Sexual intercourse with another man without condom use at least once in the past 30 days - HIV seronegative at medical screening - Report currently taking PrEP willingness to take PrEP Exclusion Criteria: - History of clinically significant withdrawal from alcohol, defined as any one of the following: a) a lifetime history of seizures, delirium, or hallucinations during alcohol withdrawal; b) a Clinical Institute Withdrawal Assessment scale score > 8; c) a report of drinking to avoid withdrawal symptoms in the past 12 months; or d) a lifetime history of medical treatment for withdrawal. - Self report injection drug use - DSM-5 criteria for moderate or severe current substance use disorder besides alcohol and nicotine. - Serious psychiatric symptoms - Use of medications that interfere with PrEP including diuretics, nephrotoxic drugs, non-steroidal anti-inflammatory drugs, antiretroviral drugs or other drugs that may interfere with tenofovir excretion - Active hepatitis B infection - The following medical exclusions: serious or life-threatening conditions; inadequate biochemical, hepatic, hematologic, or pancreatic function according to laboratory testing - Participant reports currently taking injectable PrEP

Study Design


Intervention

Drug:
PrEP acronym (pre-exposure prophylaxis)
A daily tablet containing 245 mg of tenofovir disoproxil fumarate and 200 mg emtricitabine (Truvada; Gilead Sciences) for up to 30 days.
Behavioral:
Initial Web Survey
Web-based assessment questions regarding alcohol and other substance use and sexual health behaviors
Interactive Voice Response (IVR) monitoring
Daily telephone-based assessment on alcohol and other substance use, sexual health behavior and PrEP taking
Educational material on alcohol and sexual health behavior
Educational material to provide information, resources and techniques to enhance awareness regarding alcohol and other substance use, along with sexual health behavior.
Interactive Voice Response (IVR) assessment with personalized information
Daily telephone-based assessment on alcohol and other substance use, sexual health behavior and PrEP taking with personalized and information based on daily IVR responses
Personalized information based on web-based survey responses & standardized information
Personalized and information on alcohol use and sexual health behavior based on responses to the web-based survey along with standardized information.

Locations

Country Name City State
United States University of Florida Gainesville Florida

Sponsors (2)

Lead Sponsor Collaborator
University of Florida National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in quantity of drinks per week Change in self-reported number of alcoholic drinks per week Baseline up to 1 and 6-month follow-up
Primary Change in peak drinking quantity Change in self-reported number of alcoholic drinks consumed on one's peak drinking day in the past 30 days Baseline up to 1 and 6-month follow-up
Primary PrEP levels in blood at end of intervention period Determine whether or not participants have therapeutic levels of PrEP in their blood samples 1-month follow-up
Primary PrEP levels in blood at the end of the follow-up period Determine whether or not participants have therapeutic levels of PrEP in their blood samples 6-month follow-up
Primary PrEP prescription fill with supporting documentation in the intervention period Observation of whether or not a participant opts to fill a prescription for PrEP in the intervention period based on pharmacy documentation during the 1-month intervention period
Primary PrEP prescription fills with supporting documentation during the follow-up period Observation of prescription fills for PrEP with documentation during the follow-up period based on pharmacy documentation the 6-month follow-up period
Secondary Reduced alcohol use as a reason for adherence to PrEP Test reductions in alcohol use following the intervention as a possible mechanism underlying relationships between the intervention and adherence to PrEP Baseline up to 1 and 6-month follow-up
Secondary Change in perceived risk of HIV as a reason for adherence to PrEP Test increase in Perceived Risk of HIV Scale score following the intervention as a possible mechanism underlying relationships between the intervention and adherence to PrEP Baseline up to 1 and 6-month follow-up
Secondary Change in sexual risk behavior as a reason for adherence to PrEP Test reduction in Risk Assessment Battery score following the intervention as a possible mechanism underlying relationships between the intervention and adherence to PrEP Baseline up to 1 and 6-month follow-up
Secondary Increased motivation for behavior change as a reason for adherence to PrEP Test increased score on the Contemplation Ladder for motivation to avoid risky sexual health behavior, to take PrEP and to reduce drinking following the intervention as a possible mechanism underlying relationships between the intervention and adherence to PrEP Baseline up to 1 and 6-month follow-up
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05806840 - Rapid Adaptation to Prevent Drug Use N/A
Recruiting NCT06003725 - Cultural Adaptation of Drug Treatment for DJJ Youth N/A
Recruiting NCT05414344 - A Brief Intervention for Alcohol Users With Interpersonal Trauma N/A
Recruiting NCT05768815 - Optimizing Mental Health for Infants Exposed to Early Adversity: A Comparison of Breaking the Cycle and Maxxine Wright N/A
Completed NCT05606601 - An Online Intervention Addressing Mental Health and Substance Use in University Students N/A
Completed NCT03489434 - Technology-Based Prevention for Adolescents in Primary Care N/A
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Recruiting NCT05899101 - The Impact of Opioid and Cannabis Exposure on Fetal Growth
Completed NCT02990026 - Specialty Mental Health Probation in North Carolina N/A
Not yet recruiting NCT06116266 - Collaborative Care for Polysubstance Use in Primary Care Settings (Co-Care) N/A
Not yet recruiting NCT03249428 - E-Cigarette Inner City RCT N/A
Active, not recruiting NCT03129334 - Preventing Prescription Drug Abuse in Middle School Students N/A
Completed NCT04183400 - Safety Awareness For Empowerment (SAFE): An RCT With Young People Experiencing Homelessness N/A
Completed NCT02112201 - The ProGirls Study N/A
Completed NCT01752998 - Treating Chronic Pain in Buprenorphine Patients in Primary Care Settings N/A
Terminated NCT01661517 - Brief Intervention and Referral to Treatment With Substance Use Disorders in the Emergency Room Setting Phase 0
Completed NCT01511380 - Targeting HIV Risk Behaviors in Juvenile Drug Court-Involved Youth Phase 2
Completed NCT01351454 - Behavioral Depression Treatment for African American HIV-infected Substance Users N/A
Completed NCT01154309 - Group CBT for Depression and AOD Disorders Phase 1
Completed NCT01025674 - Randomized Trial of the Positive Action Program in Chicago Schools and Extension to Grade 8 N/A